Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04999969 · ClinicalTrials.gov registry record · Phase 2
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
A Phase 2 study of Locally Advanced or Metastatic Solid Tumours, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
- 20
- Study locations
NCT04999969 is a Phase 2 study of Locally Advanced or Metastatic Solid Tumours that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 126 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT04999969, a Phase 2 study of Locally Advanced or Metastatic Solid Tumours, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
- 20
- Study locations
Study Summary
The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG Durvalumab
- DRUG AZD0171
Study Locations (20)
California
- Research Site - La Jolla
- Research Site - Los Angeles
- Research Site - Orange
- Research Site - Ventura
Ontario
- Research Site - Barrie
- Research Site - Toronto
- Research Site - Toronto
Michigan
- Research Site - Ann Arbor
- Research Site - Grand Rapids
New York
- Research Site - Buffalo
- Research Site - New York
Georgia
- Research Site - Atlanta
Idaho
- Research Site - Coeur d'Alene
Massachusetts
- Research Site - Boston
Oregon
- Research Site - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2021-12-10 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04999969
The ClinicalTrials.gov registry entry for NCT04999969 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced or Metastatic Solid Tumours appearing as the primary indexed condition, and to 4 interventions - of which Gemcitabine is the first listed.
NCT04999969 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Ontario, Michigan.
Frequently Asked Questions
What is clinical trial NCT04999969 about?
NCT04999969 is a clinical study titled "Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours". The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).
What is the current status of trial NCT04999969?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2021-12-10. Estimated completion is 2026-06-30.
What conditions does trial NCT04999969 study?
This clinical trial studies the following conditions: Locally Advanced or Metastatic Solid Tumours.
What interventions are being tested in trial NCT04999969?
The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG), Durvalumab (DRUG), AZD0171 (DRUG).
Who is sponsoring clinical trial NCT04999969?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04999969 being conducted?
This trial has 20 study locations across California, Georgia, Idaho, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.